中文

News Center

Doer Biologics Announced First Patient Dosed in Phase 2 Study of DR10624, reported by mainstream media

2024/10/09

Read more

World's First Triple Agonist DR10624 Completes Full Enrollment in Phase 1b/2a Clinical Trial for Obesity with Hypertriglyceridemia

2024/07/09

Read more

Zhejiang Doer Biologics Announces License Agreement with BioNTech

2023/07/11

Read more

Many mainstream media reported the collaboration between Zhejiang Doer Biologics and MSD

2022/12/19

Read more

Reported by PR Newswire published

2022/12/17

Read more

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD

2022/12/16

Read more

Doer Biologics signs licensing agreement with Lonza to develop multi-specific biotherapeutics using XS Pichia

2022/12/09

Read more

Doer Biologics interview by Biopharma Reporter published

2021/12/16

Read more

PR post reshared by Bioprocess international

2021/12/14

Read more

Doer Biologics CEO invited as speaker at BIT 2021

2021/04/10

Read more